Search Results - "Witztum, J.L"

Rationale and design of a clinical trial to assess Lp(a) lowering with ionis-apo(a)-LRX in patients undergoing apheresis for elevated Lp(a) and recurrent cardiovascular events by Moriarty, P.M, Thiessen, E.S, Witztum, J.L, Viney, N.J, Tsimikas, S

Get full text

Defining the mechanism of lipoprotein(a) [Lp(a)] lowering by alirocumab in transgenic mouse models by Yeang, C, Miu, P, Green, S, Yang, X, Hung, M.Y, Witztum, J.L, Tsimikas, S

Get full text

Natural temporal variability in Lp(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx antisense oligonucleotide clinical trials by Viney, N.J, Marcovina, S, Tami, J, Xia, S, Witztum, J.L, Tsimikas, S

Get full text

The oxidation hypothesis of atherosclerosis by Witztum, J L

Get more information

Expression of E06, a natural monoclonal antibody targeted to oxidized phospholipids (OXPL), attenuates the progression of aortic sclerosis in aged hyperlipidemic mice by Yeang, C, Hung, M.Y, Pattison, J, Bowden, K, Dalton, N, Peterson, K.L, Witztum, J.L, Tsimikas, S, Que, X

Get full text

Population and assay thresholds for the predictive value of lipoprotein(a) for risk of coronary artery disease: The EPIC-Norfolk prospective population study by Verbeek, R, Boekholdt, S.M, Stoekenbroek, R.M, Hovingh, G.K, Witztum, J.L, Wareham, N.J, Sandhu, M.S, Khaw, K.T, Tsimikas, S

Get full text

Plasma apolipoprotein CIII levels and incident coronary artery disease risk: The EPIC-Norfolk prospective population study by van Capelleveen, J, Moens, S.J. Bernelot, Yang, X, Wareham, N.T, Khaw, K.T, Stroes, E.S.G, Witztum, J.L, Hovingh, G.K, Boekholdt, S.M, Tsimikas, S

Get full text

ISIS-ANGPTL3RX , an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers by Brandt, T.A, Lee, R.G, Digenio, A, Graham, M.G, Crooke, R.M, Hughes, S.G, Singleton, W, Witztum, J.L, Tsimikas, S

Get full text

Prevalence of LPA single nucleotide polymorphisms and isoforms in patients enrolled in a phase 2 IONIS-APO(a)Rx clinical trial by Stroes, E.S, van der Valk, F.M, Gaudet, D, Gouni-Berthold, I, Riksen, N.P, Steinhagen-Thiessen, E, Isermann, B, Nordestgaard, B, Viney, N.J, Marcovina, S, Hughes, S.G, Tami, J, Xia, S, Witztum, J.L, Tsimikas, S

Get full text

The APPROACH Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) by Gaudet, D, Digenio, A, Alexander, V.J, Arca, M, Jones, A.F, Stroes, E, Bergeron, J, Civeira, F, Hemphill, L, Blom, D.J, Flaim, J, Hughes, S, Geary, R, Tsimikas, S, Witztum, J.L, Bruckert, E

Get full text

Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements by Yeang, C., Su, F., Witztum, J.L., Tsimikas, S.

Get full text

Interventional hepatic ApoC-III knockdown improves atherosclerotic plaque stability and remodeling via lowering remnant lipoproteins by Gordts, P., Ramms, B., Pessentheiner, A., Sun, X., Ducasa, G.M., Tsimikas, S., Witztum, J.L.

Get full text

Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of antisense oligonucleotides by Tsimikas, S., Karwatowska-Prokopczuk, E., Clouet-Foraison, N., Xia, S., Viney, N., Witztum, J.L., Marcovina, S.M.

Get full text

Effects of patient characteristics on volanesorsen efficacy: Subgroup analysis of approach by Witztum, J.L., Gaudet, D., Freedman, S., Alexander, V.J., Arca, M., Stroes, E.S., Bergeron, J., Soran, H., Civeira, F., Tsimikas, S., Blom, D.J., Bruckert, E.

Get full text

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study by van Capelleveen, Julian C, Bernelot Moens, Sophie J, Yang, Xiaohong, Kastelein, John J P, Wareham, Nicholas J, Zwinderman, Aeilko H, Stroes, Erik S G, Witztum, Joseph L, Hovingh, G Kees, Khaw, Kay-Tee, Boekholdt, S Matthijs, Tsimikas, Sotirios

“…Apolipoprotein C-III (apoC-III) is a key regulator of triglyceride metabolism. Elevated triglyceride-rich lipoproteins and apoC-III levels are causally linked…”
Get full text

The human milk oligosaccharide 3’sialyllactose promotes inflammation resolution and reduces atherosclerosis development by Pessentheiner, A., Spann, N., Collins, C., Ramms, B., Chiang, A., Wang, Y., Quach, A., Booshehri, L., Hammond, A., Tognaccini, C., Latasiewicz, J., Witztum, J.L., Hoffman, H., Lewis, N., Glass, C., Bode, L., Gordts, P.

Get full text

Residual inflammatory risk increases endothelial metabolism, thereby facilitating sustained vascular inflammation and leukocyte extravasation by Hanford, K.M.L., Schnitzler, J.G., Hoogeveen, R.M., Ali, K., Prange, K.H.M., Weeghel, M.V., Versloot, M., Waissi, F., Houtkooper, R., De Kleijn, D.P.V., De Winther, M., Koschinsky, M.L., Tsimikas, S., Witztum, J.L., Stroes, E.S.G., Kroon, J.

Get full text

Atherogenic lipoprotein(A) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation by Schnitzler, J.G., Hoogeveen, R.M., Ali, L., Prange, K., Weeghel, M.V., Versloot, M., Waissi, F., Houtkooper, R., De Kleijn, D.P.V., De Winther, M., Koschinsky, M., Tsimikas, S., Witztum, J.L., Stroes, E., Kroon, J.

Get full text

P1761Diabetic status influences the effect of pro-inflammatory interleukin-1 genotypes on lipoprotein(a) mediated risk of coronary artery disease and cardiovascular events by Naka, K.K., Bechlioulis, A., Douchette-Stamm, L., Wilkins, L., Marini, A., Bougiakli, M., Giannitsi, S., Rogus, J., Kornman, K., Witztum, J.L., Tsimikas, S., Michalis, L.K.

Get full text

Expression of the peroxisome proliferator-activated receptor gamma (PPAR gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein by Ricote, M. (University of California at San Diego, La Jolla, CA.), Huang, J, Fajas, L, Li, A, Welch, J, Najib, J, Witztum, J.L, Auwerx, J, Palinski, W, Glass, C.K

“…The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a ligand-dependent transcription factor that has been demonstrated to regulate fat cell…”
Get full text